IRIS
MAZZASCHI, GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.074
NA - Nord America 1.941
AS - Asia 1.307
SA - Sud America 225
AF - Africa 38
OC - Oceania 9
Totale 5.594
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.900
IT - Italia 679
SG - Singapore 557
CN - Cina 364
IE - Irlanda 326
SE - Svezia 270
BR - Brasile 206
DE - Germania 200
HK - Hong Kong 190
NL - Olanda 123
FR - Francia 106
AT - Austria 72
FI - Finlandia 68
IN - India 63
RU - Federazione Russa 60
GB - Regno Unito 52
BD - Bangladesh 37
CZ - Repubblica Ceca 28
BE - Belgio 27
CI - Costa d'Avorio 26
TR - Turchia 25
CA - Canada 21
MX - Messico 13
ID - Indonesia 12
UA - Ucraina 11
AR - Argentina 10
PK - Pakistan 10
IR - Iran 9
AU - Australia 8
ES - Italia 8
LU - Lussemburgo 8
PL - Polonia 8
LT - Lituania 7
UZ - Uzbekistan 6
JP - Giappone 5
MA - Marocco 5
ZA - Sudafrica 5
AZ - Azerbaigian 4
EE - Estonia 4
IL - Israele 4
IQ - Iraq 4
KR - Corea 4
CH - Svizzera 3
DK - Danimarca 3
BG - Bulgaria 2
CO - Colombia 2
EC - Ecuador 2
KG - Kirghizistan 2
MD - Moldavia 2
NO - Norvegia 2
PS - Palestinian Territory 2
TT - Trinidad e Tobago 2
VE - Venezuela 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
BB - Barbados 1
BO - Bolivia 1
BY - Bielorussia 1
CL - Cile 1
DO - Repubblica Dominicana 1
EG - Egitto 1
HN - Honduras 1
HU - Ungheria 1
JM - Giamaica 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
MK - Macedonia 1
MT - Malta 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
PH - Filippine 1
RS - Serbia 1
SA - Arabia Saudita 1
TH - Thailandia 1
TW - Taiwan 1
Totale 5.594
Salva come PNG Salva come JPEG
Città #
Singapore 391
Dublin 323
Chandler 313
Santa Clara 246
Hong Kong 184
Parma 171
Ashburn 165
Boardman 133
Ann Arbor 126
Shanghai 97
Munich 76
Beijing 64
New York 64
Bologna 62
Vienna 56
Milan 42
Bremen 41
Helsinki 39
Princeton 38
Moscow 33
Dearborn 31
Marseille 31
Los Angeles 28
Abidjan 26
Frankfurt am Main 26
Brussels 25
Hefei 25
Nanjing 24
Rome 23
West Jordan 22
Verona 21
Bengaluru 19
Dallas 19
Modena 19
Turku 19
Des Moines 18
Nuremberg 18
Chicago 16
Brno 15
Columbus 15
Rio Saliceto 15
The Dalles 15
Wilmington 15
São Paulo 13
London 12
Fremont 11
Guangzhou 11
Jinan 11
Pune 11
Toronto 11
Amsterdam 10
Düsseldorf 10
Izmir 10
Torrile 10
Chongqing 9
Jakarta 9
Olomouc 9
Sorbolo 9
Trento 9
Ardea 8
Boston 8
Falls Church 8
Nanchang 8
Reggio Emilia 8
San Mateo 8
Guarulhos 7
Hangzhou 7
Seattle 7
Atlanta 6
Belo Horizonte 6
Brooklyn 6
Curitiba 6
Houston 6
Kocaeli 6
North Bergen 6
Portsmouth 6
Venice 6
Bolzano 5
Brescia 5
Florence 5
Hebei 5
Jiaxing 5
Johannesburg 5
Kunming 5
Lauterbourg 5
Melbourne 5
Montreal 5
Naples 5
Norwalk 5
Redwood City 5
Rio de Janeiro 5
Salvador 5
Tashkent 5
Tianjin 5
Valencia 5
Verdellino 5
Woodbridge 5
Zhengzhou 5
Assago 4
Baku 4
Totale 3.550
Salva come PNG Salva come JPEG
Nome #
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 135
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients 135
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 134
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 126
Imatinib mesylate-induced cardiomyopathy involves resident cardiac progenitors 120
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 112
Low PD-1 expression in Cytotoxic CD8+ Tumor infiltrating Lymphocytes Confers an Immune Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value 111
INTEGRATION OF TISSUE PD-1/PD-L1 IMMUNE CHECKPOINT WITH COMPUTED TOMOGRAPHY (CT) BASED TEXTURE ANALYSIS EXHIBITS HIGH PROGNOSTIC IMPACE ON SURGICALLY RESECTED NON SMALL CELL LUNG CANCER (NSCLC) 108
Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer 102
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 101
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 97
BLOOD AND LYMPHATIC VESSELS CONSTITUTE AN ESSENTIAL COMPONENT OF THE IMMUNE MICROENVIRONMENT AND ITS IMPACT ON NON SMALL CELL LUNG CANCER (NSCLC) CLINICAL OUTCOME 96
Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis 96
Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer 90
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 89
SURGICAL SAMPLING IS AN EMERGING ISSUE IN THE ASSESSMENT OF THE IMMUNE CONTEXTURE IN NON SMALL CELL LUNG CANCER (NSCLC) 89
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 88
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 88
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 87
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC 87
227P Sexual dimorphism in immune profile of early and advanced NSCLC 86
Favorable clinical outcome and response to immunotherapy share a common PD-L1/PD-1 based NSCLC immune contexture 85
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 84
IMPACT OF THE TISSUE DISTRIBUTION OF SUBPOPULATIONS OF TILS AND PD-L1 EXPRESSION ON THE CLINICAL OUTCOME OF NSCLC 82
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 79
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 78
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 78
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 77
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma 76
Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer 76
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 75
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 72
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 71
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 71
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 70
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 70
91 Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors 69
THE ROLE OF BLOOD CHOLESTEROL QUALITY IN PATIENTS WITH ADVANCED CANCER RECEIVING IMMUNE CHECKPOINT INHIBITORS 67
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 63
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 63
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 60
Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma 60
Differentially regulated high-throughput CT imaging features correlate to distinct tumor immune contextures portraying a radiomic signature with prognostic impact on surgically resected NSCLC 60
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis 58
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 57
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors 53
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score 51
The role of c-met as a biomarker and player in innate and acquired resistance in non-small-cell lung cancer: Two new mutations warrant further studies 51
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 50
The radiological appearances of lung cancer treated with immunotherapy: a review 49
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario 49
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study 49
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology 49
Unraveling the link between cholesterol and immune system in cancer: From biological mechanistic insights to clinical evidence. A narrative review 48
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 48
Evaluation of PBRM1, PD-L1, CD31, and CD4/CD8 ratio as a predictive signature of response to VEGFR-TKI–based therapy in patients with metastatic renal cell carcinoma (mRCC) with IMDC intermediate prognosis: Results from the APAChE-I Study 47
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 45
Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature 44
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 43
Deciphering the different patterns of acquired resistance in immunotherapy treated NSCLC patients through an integrated clinical and blood immuneinflammatory profiling 42
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 41
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis 41
Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC 40
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 40
Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer 40
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors 38
Integration of tissue and circulating parameters identifies a favorable immune profile in NSCLC patients treated with nivolumab 38
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review 37
Drug-drug interactions (DDIs) in elderly patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib within the multicenter prospective trial ZEBRA/Meet-URO 9 36
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 35
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy 35
Advanced CT imaging features reflect distinct tissue immune profiles and exhibit high prognostic impact on NSCLC 35
1599P Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study 35
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 35
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 34
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study 34
9P Identification of a μCT-based radiomic signature of CD8+ tumour infiltrating lymphocytes in an orthotopic murine model 34
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer 33
What Is the Real Impact of Concomitant Antibiotics or Proton Pump Inhibitors on Efficacy of Atezolizumab-Based Regimens in Patients With NSCLC? 31
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 30
A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study 30
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations 29
The distinct prognostic impact of circulating lipid profile according to neutrophil to lymphocyte ratio in patients with advanced solid tumors treated with immune check point inhibitors. 28
Burnout and Oncology: an irreparable paradigm or a manageable condition? Prevention strategies to reduce Burnout in Oncology Health Care Professionals 27
EP.15B.05 Predictors of 30-Day Mortality after Systemic Therapy in Hospitalized Lung Cancer Patients: A Retrospective Single-Center Observational Study 27
Immune checkpoint inhibitors in hepatocellular cancer patient with congenital haemophilia A 27
Evaluation of PBRM1, PD-L1, CD31 and CD4/CD8 ratio as predictive biomarkers of response to VEGFR-TKI-based therapy in metastatic renal cell carcinoma (mRCC) patients with IMDC intermediate prognosis: Results from the APAChE-I study 27
Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma 26
Abscopal effect as part of treatment of oligometastatic head and neck cancer: A case report 25
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences 24
Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC 23
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations 23
Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review 23
Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups 23
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 23
Identification of a radio-immune signature with high prognostic value in surgically resected NSCLC 16
Non-homogenous intratumor ionizing radiation doses synergize with PD1 and CXCR2 blockade 16
The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab 13
Totale 5.748
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.244
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.244
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207 0 0 0 0 0 0 0 0 0 0 0 7
2020/2021251 10 11 10 23 33 33 16 18 24 17 35 21
2021/2022272 13 13 15 19 5 12 60 10 6 10 21 88
2022/20231.306 121 129 72 109 143 143 38 73 391 7 56 24
2023/2024876 33 60 28 36 110 157 97 36 62 80 49 128
2024/20252.666 92 177 226 197 261 244 183 132 253 271 237 393
Totale 5.748